Bayforest Capital Ltd Makes New $939,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Bayforest Capital Ltd has made a new investment of approximately $939,000 in Arrowhead Pharmaceuticals, acquiring 59,403 shares during the second quarter.
• Several institutional investors, including GAMMA Investing LLC and CWM LLC, have significantly increased their stakes in Arrowhead Pharmaceuticals, indicating strong institutional interest in the company.
• Analysts have a mixed outlook on Arrowhead Pharmaceuticals, with ratings ranging from "Strong Buy" to "Sell," and a consensus price target of $43.14.

Bayforest Capital Ltd purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 59,403 shares of the biotechnology company's stock, valued at approximately $939,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARWR. GAMMA Investing LLC raised its stake in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares in the last quarter. CWM LLC raised its stake in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares in the last quarter. KBC Group NV raised its stake in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 2,132 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 1st quarter worth approximately $133,000. Institutional investors own 62.61% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ARWR shares. Royal Bank Of Canada dropped their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.14.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider directly owned 212,122 shares of the company's stock, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 60,000 shares of company stock worth $1,725,000. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Stock Up 2.4%

ARWR stock opened at $36.25 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The stock has a market capitalization of $5.01 billion, a price-to-earnings ratio of -28.32 and a beta of 1.13. The business's fifty day moving average price is $26.99 and its two-hundred day moving average price is $19.13. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $39.42.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the business posted ($1.38) earnings per share. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.